Alpha Cognition (NASDAQ:ACOG) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Alpha Cognition (NASDAQ:ACOGFree Report) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $20.00 price objective on the stock.

Alpha Cognition Stock Up 1.9 %

Shares of ACOG stock opened at $5.80 on Tuesday. Alpha Cognition has a 52-week low of $4.66 and a 52-week high of $7.00. The stock has a 50-day moving average price of $5.92. The company has a market cap of $92.92 million, a P/E ratio of -2.27 and a beta of 2.50.

Institutional Investors Weigh In On Alpha Cognition

A number of institutional investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. bought a new stake in Alpha Cognition in the 4th quarter worth about $3,652,000. Bleichroeder LP purchased a new position in Alpha Cognition in the fourth quarter valued at about $1,024,000. Alyeska Investment Group L.P. purchased a new position in Alpha Cognition in the fourth quarter valued at about $2,356,000. Manatuck Hill Partners LLC purchased a new position in Alpha Cognition in the fourth quarter valued at about $395,000. Finally, Tudor Investment Corp ET AL purchased a new position in Alpha Cognition in the fourth quarter valued at about $412,000.

About Alpha Cognition

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

See Also

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.